Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information.
Document Type
Article
Publication Date
10-15-2024
Publication Title
Toxins
Abstract
The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety among BoNTAs is difficult because, per regulatory authorities, units of BoNTA activity are not interchangeable. Dysphagia and muscle weakness are widely considered two key adverse events to monitor closely in the treatment of CD. This integrated analysis compared the safety of BoNTAs approved for CD in the US by evaluating relationships between the incidence of dysphagia and muscle weakness in prescribing information and the core neurotoxin content. Coefficients The coefficients of determination (R
Volume
16
Issue
10
First Page
442
Recommended Citation
Dashtipour K, Lee HS, Ellenbogen A, Kazerooni R, Gross TM, Hollander DA, Gallagher CJ. Dysphagia and muscle weakness secondary to botulinum toxin type A treatment of cervical dystonia: a drug class analysis of prescribing information. Toxins. 2024 Oct 15;16(10):442. doi: 10.3390/toxins16100442. PMID: 39453218.
DOI
10.3390/toxins16100442
ISSN
2072-6651
PubMed ID
39453218
